Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Skye Bioscience, Inc. - Common Stock
(NQ:
SKYE
)
1.380
-0.070 (-4.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Skye Bioscience, Inc. - Common Stock
MarketBeat Week in Review – 10/7 - 10/11
October 12, 2024
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
October 09, 2024
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Via
MarketBeat
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
October 04, 2024
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.
Via
MarketBeat
Topics
Bankruptcy
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 16, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 08, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
August 04, 2024
From
The Schall Law Firm
Via
Business Wire
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
July 24, 2024
From
Beacon Biosignals
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.